Physician profile
Robert D Smith
NPI 1245244060
$2,669.39
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $980 · 2020: $777 · 2021: $796 · 2022: $27.66 · 2023: $23.64 · 2024: $65.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $89.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $89.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $678.55 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $450.65 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $291.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $283.76 | 2019-2021 | |
| Lilly USA, LLC | $196.24 | 2019-2021 | |
| Glaxosmithkline, LLC. | $180.84 | 2019-2021 | |
| Novo Nordisk INC | $149.90 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $129.22 | 2019-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.00 | 2019-2023 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $59.13 | 2019 | |
| Abbvie INC. | $29.75 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $20.76 | 2019 | |
| Alkermes, INC. | $19.60 | 2019 | |
| Amarin Pharma, INC. | $18.63 | 2021 | |
| Abbott Laboratories | $17.36 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.63 | 2019 | |
| Sanofi Pasteur INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.